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Abstract 
Objective: We investigated the prevalence of and risk factors associated with initiating nonmedical prescription opi-
oid use (NMPOU) before and after illegal drugs using data from two linked cohort studies of street youth and adults 
who use illegal drugs in Vancouver, Canada. All participants who attended a study visit between 2013 and 2016 were 
eligible for the primary analyses.
Results: Among 512 youth and 833 adult participants, the prevalence of NMPOU was extremely high (88% among 
street youth; 90% among adults), and over one-third of those who reported engaging in NMPOU had initiated 
NMPOU before illegal drug use (vs. transitioning from illegal drugs to NMPOU). Participants who reported either tran-
sitioning to or from NMPOU had higher risk profiles, particularly related to substance use, when compared with those 
who reported never engaging in NMPOU. Sub-analyses restricted to only those who engaged in NMPOU found few 
statistically significant differences between those who initiated NMPOU prior to illegal drugs versus those who initi-
ated illegal drugs prior to NMPOU. Findings suggest that among people who use illegal drugs, early NMPOU trajecto-
ries do not appear to critically shape future patterns and practices.
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Introduction
As nonmedical prescription opioid use (NMPOU) con-
tinues to rise across North America, researchers have 
identified an alarming trend of individuals initiating 
NMPOU and then later transitioning to using illegal 
drugs, such as heroin, cocaine, crack, and crystal meth-
amphetamine [1–5]. Among a sample of people who use 
heroin in the United States, researchers found that the 
prevalence of engaging in NMPOU before transition-
ing to heroin use increased from 64% in 2002–2004 to 
83% in 2008–2010 [6]; the prevalence of this particular 
trajectory was 40% among young heroin injectors in San 
Diego [5].
Previous research has found key differences in employ-
ment and education outcomes between those who engage 
in illegal drug use and those who engage in NMPOU [7–
9]; however, fewer studies have compared transitions to 
and from NMPOU with those who only use illegal drugs, 
as well as within-group differences among those who 
engage in NMPOU. Given these gaps in knowledge, the 
present study investigates the prevalence of, and risk fac-
tors associated with, transitioning from NMPOU to ille-
gal drugs vs. transitioning from illegal drugs to NMPOU 
use among a sample of street youth and adults who use 
illegal drugs in Vancouver, Canada.
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Main text
Methods
Data for this cross-sectional research are drawn from two 
open prospective cohort studies of youth and adults who 
use illegal drugs with harmonized procedures and survey 
instruments: the At-Risk Youth Study (ARYS) and the 
Vancouver Injection Drug Users Study (VIDUS). Recruit-
ment for both cohorts uses extensive snowball sampling, 
self-referral, and street outreach. The eligibility criteria 
for participating in ARYS includes: being between the 
ages of 14 and 26; use of an illegal drug other than, or 
in addition to, cannabis in the past month; and “street-
involvement”, defined as being recently homeless or hav-
ing used services designated for street youth [10–13]. The 
VIDUS cohort includes adults (≥18 years of age) who are 
HIV-negative and who injected drugs at least once in the 
previous month. All participants must provide written 
informed consent to participate. At baseline and every 
6  months thereafter, participants in both cohorts com-
plete a harmonized interviewer-administered question-
naire and receive a stipend ($30 CDN) for their time. The 
ARYS and VIDUS studies receive ethical approval from 
the University of British Columbia/Providence Health 
Care Research Ethics Board.
All ARYS and VIDUS participants were eligible for the 
primary statistical analyses, which were two analyses 
investigating risk factors associated with (i) transitioning 
from NMPOU to illegal drug use, and (ii) transitioning 
from illegal drug use to NMPOU; the comparison group 
for both analyses were participants who reported never 
engaging in NMPOU. A report of NMPOU was defined 
as ever engaging in injection or non-injection NMPOU 
(yes vs. no) between 2013 and 2016. Transitions to and 
from NMPOU were categorized based on responses to 
the following question: “Did you use prescription opioids 
when they were not prescribed for you or that you took 
only for the experience or feeling they caused before you 
had ever used any of the following hard illegal drugs: her-
oin, cocaine, crack, or crystal methamphetamine?” (yes, 
non-medical use of POs came before other hard drug 
use vs. no, non-medical use of POs came after other hard 
drug use).
The following socio-demographic, early-life, and men-
tal health variables of interest were included: age per year 
older; male gender (male vs. female); Caucasian ances-
try (white vs. non-white); ever experienced homeless-
ness, defined as having no fixed address, sleeping on the 
street, couch surfing, or staying in a shelter or hostel (yes 
vs. no); high school incompletion (yes vs. no); a baseline 
score of 13 or higher on the Childhood Trauma Ques-
tionnaire (CTQ), which indicates moderate to severe 
abuse due to physical abuse, sexual abuse, emotional 
abuse, physical neglect, and emotional neglect (yes vs. 
no); and a baseline score of 22 or higher on the Center 
for Epidemiological Studies Depression Scale (CES-D), 
which indicates a relatively higher level of depressive 
symptoms among vulnerable individuals [14] (yes vs. 
no). Multiple variables related to substance use patterns 
are also included: daily injection or non-injection heroin 
use (yes vs. no); daily injection or non-injection of stim-
ulant drugs, including daily use of either crack cocaine, 
cocaine, or crystal methamphetamine use (yes vs. no); 
binge drug use, defined as a period of using injection or 
non-injection drugs more often than usual (yes vs. no); 
amount of money spent on drugs per day (< median vs. 
≥ median); ever experiencing a non-fatal drug overdose 
(yes vs. no); and ever accessing methadone treatment, 
which was the most widely available form of opioid ago-
nist treatment in this setting during the study period [15] 
(yes vs. no). This analysis also includes a range of socio-
structural risk factors hypothesized to be associated with 
this transition pattern: emergency room visit (yes vs. no); 
experience of violence (yes vs. no); ever been incarcer-
ated (yes vs. no); regular employment, defined as having a 
regular job, temporary work, or being self-employed (yes 
vs. no); drug dealing, defined as selling drugs as a source 
of income (yes vs. no); and ever engaging in sex work, 
defined as exchanging sex for money, drugs, gifts, food, 
clothes, shelter or favours (yes vs. no). All variables refer 
to activities, behaviours, and experiences in the previous 
6 months unless otherwise indicated.
Questions related to NMPOU were added to the 
ARYS and VIDUS survey instrument in June 2013. For 
participants reporting NMPOU, data for the outcome 
were drawn from the first study visit where participants 
reported ever engaging in NMPOU; data for the inde-
pendent variables were drawn from participants’ baseline 
study visit. For participants who did not report engaging 
in NMPOU between 2013 and 2016, data for the out-
come and independent variables were also drawn from 
participants’ baseline study visit.
To assess factors associated with transitions to and 
from NMPOU (vs. never engaging in NMPOU), bivari-
ate logistic regression analyses were conducted for ARYS 
and VIDUS participants separately. For variables sig-
nificant at p < 0.10 in the bivariate analyses, a full multi-
variate model was constructed. The model with the best 
overall fit was selected using the Akaike Information 
Criterion (AIC). All statistical analyses were performed 
using R version 3.2.4 [16]. All p-values are two sided.
Sub-analyses were conducted using a restricted sam-
ple of only those who reported engaging in NMPOU. 
The outcome of these analyses was transitioning from 
NMPOU to illegal drug use (vs. transitioning from ille-
gal drugs to NMPOU), and these analyses used the same 
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independent variables and statistical approach as the pri-
mary analysis.
Results
A total 512 ARYS and 833 VIDUS participants were eli-
gible for the primary analyses. A high proportion of 
these cohort participants reported ever engaging in 
NMPOU during a study visit between 2013 and 2016 
(ARYS: n  =  452, 88%; VIDUS: n  =  750, 90%). Among 
512 ARYS participants, 334 (65%) were male, 314 (61%) 
were of Caucasian ethnicity, and the median age was 
24 years (Inter-Quartile Range [IQR] 22–27). The major-
ity of VIDUS participants were male (n = 530, 64%) and 
Caucasian (n = 487, 59%); the median age was 47 years 
(IQR 38–54). Within each cohort, 160 (31%) ARYS 
participants (total n =  512) and 276 (33%) VIDUS par-
ticipants (total n  =  833) reported transitioning from 
NMPOU to illegal drugs. The descriptive characteristics 
of ARYS and VIDUS participants are displayed in Table 1, 
and the bivariate analyses investigating PO-related sub-
stance use trajectories are shown in Table 2. The results 
from the multivariate analyses are displayed in Table 3.
A total of 452 ARYS and 750 VIDUS participants 
reported ever engaging in NMPOU and were eligible 
for inclusion in the sub-analyses. The full results from 
the sub-analyses investigating transitions to and from 
Table 1 ARYS and VIDUS participant characteristics stratified by trajectory of nonmedical prescription opioid use 
(NMPOU) (n = 1345)
a Comparison is yes vs. no
b Refers to activities, behaviours, and experiences in the last 6 months
c Includes injection and non-injection drug use
d Includes crack cocaine, cocaine, or crystal methamphetamine use
e Comparison is <median vs. ≥ median
Characteristic ARYS (n = 512) VIDUS (n = 833)
Never NMPOU (%) 
(n = 60)
NMPOU first (%) 
(n = 160)
Illegal drugs first 
(%) (n = 292)
Never NMPOU (%) 
(n = 83)
NMPOU first (%) 
(n = 276)
Illegal drugs first 
(%) (n = 474)
Age per year older 
[M (IQR)]
26 (22–28) 24 (21–26) 24 (22–27) 49 (42–56) 48 (38–54) 47 (37–54)
Male  gendera 37 (61.7) 115 (71.9) 182 (62.3) 51 (61.4) 169 (61.2) 310 (65.4)
Caucasian  ancestrya 35 (58.3) 97 (60.6) 182 (62.3) 37 (44.6) 158 (57.2) 292 (61.6)
Homelessa 55 (91.7) 153 (95.6) 275 (94.2) 72 (86.7) 260 (94.2) 444 (93.7)
High school 
 incompletiona
27 (45.0) 56 (35.0) 100 (34.2) 39 (47.0) 140 (50.7) 231 (48.7)
Daily heroin  usea,b,c 5 (8.3) 45 (28.1) 89 (30.5) 10 (12.0) 77 (27.9) 125 (26.4)
Daily stimulant 
 usea,b,c,d
22 (36.7) 43 (26.9) 102 (34.9) 21 (25.3) 82 (29.7) 139 (29.3)
Binge drug  usea,b,c 21 (35.0) 90 (56.3) 181 (62.0) 22 (26.5) 101 (36.6) 175 (36.9)
$ spent on drugs/
dayb,e
22 (36.7) 64 (40.0) 114 (39.0) 22 (26.5) 108 (39.1) 187 (39.5)
Non-fatal 
 overdosea,c
27 (45.0) 90 (56.3) 169 (57.9) 34 (41.0) 177 (64.1) 325 (68.6)
Methadone 
 treatmenta
7 (11.7) 42 (26.3) 87 (29.8) 39 (47.0) 218 (79.0) 374 (78.9)
Emergency room 
 visita,b
23 (38.3) 58 (36.3) 131 (44.9) 16 (19.3) 82 (29.7) 151 (31.9)
Depression 
 symptomsa
26 (43.3) 87 (54.4) 160 (54.8) 40 (48.2) 155 (56.2) 241 (50.8)
Childhood  traumaa 35 (58.3) 97 (60.6) 195 (66.8) 48 (57.8) 183 (66.3) 313 (66.0)
Experience 
 violencea,b
12 (20.0) 62 (38.8) 116 (39.7) 9 (10.8) 48 (17.4) 73 (15.4)
Incarcerationa 35 (58.3) 96 (60.0) 195 (66.8) 63 (75.9) 246 (89.1) 426 (89.9)
Regular 
 employmenta,b
27 (45.0) 74 (46.3) 133 (45.5) 24 (28.9) 71 (25.7) 133 (28.1)
Drug  dealinga,b 10 (16.7) 55 (34.4) 95 (32.5) 6 (7.2) 73 (26.4) 110 (23.2)
Sex  worka 18 (30.0) 41 (25.6) 85 (29.1) 57 (68.7) 169 (61.2) 272 (57.4)
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NMPOU can be found in Additional files 1: Table S1 and 
2: Table S2 attached to this article. In brief, the bivariate 
VIDUS analysis revealed no significant risk factors asso-
ciated with transitioning from NMPOU to illegal drug 
use (p  >  0.10); no multivariate analysis was performed. 
A multivariate analysis was performed for the ARYS 
participants with male gender, daily illicit stimulant use, 
and emergency room use eligible for the final model (p < 
0.10); only male gender was significantly associated with 
transitioning from NMPOU to illegal drugs in the final 
multivariate model (Adjusted Odds Ratio [AOR] = 1.57, 
95% Confidence Interval 1.04–2.41).
Discussion
Among our sample of people who use illegal drugs in 
Vancouver, BC, the prevalence of NMPOU was extremely 
high (88% among street youth and 90% among adults), 
and over one-third of those who reported engaging in 
NMPOU had initiated NMPOU before illegal drug use 
(vs. transitioning from illegal drugs to NMPOU). Partici-
pants who reported either transitioning from NMPOU 
to illegal drugs or from illegal drugs to NMPOU shared 
many risk factors when compared with those who 
reported never engaging in NMPOU. Regardless of their 
transition trajectory, youth who engaged in NMPOU 
Table 2 Bivariate analyses investigating nonmedical prescription opioid use (NMPOU) before or after illegal drug use 
(n = 1345)
a Comparison is yes vs. no
b Refers to activities, behaviours, and experiences in the last 6 months
c Includes injection and non-injection drug use
d Includes crack cocaine, cocaine, or crystal methamphetamine use
e Comparison is <median vs. ≥ median
Characteristic ARYS (n = 512) VIDUS (n = 833)
NMPOU first  
(vs. never NMPOU)
Illicit drugs first  
(vs. never NMPOU)
NMPOU first  
(vs. never NMPOU)
Illicit drugs first  
(vs. never NMPOU)
Odds ratio  
(95% CI)
p-value Odds ratio  
(95% CI)
p-value Odds ratio  
(95% CI)
p-value Odds ratio  
(95% CI)
p-value
Age per year older 0.91 (0.84–0.99) 0.033 0.94 (0.87–1.02) 0.122 0.98 (0.95–1.00) 0.080 0.98 (0.96–1.00) 0.083
Male  gendera 1.59 (0.85–2.96) 0.146 1.03 (0.57–1.81) 0.923 0.99 (0.59–1.63) 0.972 1.19 (0.73–1.91) 0.487
Caucasian  ancestrya 1.06 (0.57–1.93) 0.861 1.13 (0.64–2.00) 0.665 1.66 (1.02–2.74) 0.043 1.99 (1.25–3.21) 0.004
Homelessa 1.99 (0.57–6.48) 0.257 1.47 (0.47–3.90) 0.467 2.48 (1.08–5.54) 0.028 2.26 (1.04–4.59) 0.029
High school 
 incompletiona
0.60 (0.33–1.12) 0.107 0.59 (0.33–1.05) 0.070 1.09 (0.66–1.80) 0.742 1.03 (0.64–1.66) 0.903
Daily heroin  usea,b,c 4.30 (1.76–12.95) 0.003 4.82 (2.04–14.19) 0.001 2.82 (1.44–6.08) 0.004 2.61 (1.37–5.53) 0.006
Daily stimulant 
 usea,b,c,d
0.63 (0.34–1.20) 0.158 0.93 (0.52–1.67) 0.798 1.25 (0.72–2.22) 0.437 1.23 (0.73–2.13) 0.455
Binge drug  usea,b,c 2.39 (1.30–4.48) 0.006 3.06 (1.73–5.54) 0.000 1.60 (0.94–2.81) 0.091 1.63 (0.98–2.80) 0.067
$ spent on drugs/
dayb,e
1.18 (0.64–2.21) 0.594 1.13 (0.64–2.05) 0.669 1.77 (1.04–3.10) 0.041 1.80 (1.08–3.10) 0.027
Non-fatal 
 overdosea,c
1.57 (0.87–2.87) 0.138 1.68 (0.96–2.95) 0.069 2.58 (1.57–4.28) < 0.001 3.14 (1.96–5.11) < 0.001
Methadone 
 treatmenta
2.69 (1.20–6.91) 0.024 3.21 (1.49–8.00) 0.006 4.24 (2.53–7.16) < 0.001 4.22 (2.60–6.87) < 0.001
Emergency room 
 visita,b
0.91 (0.50–1.70) 0.775 1.31 (0.75–2.34) 0.354 1.77 (0.99–3.33) 0.064 1.96 (1.12–3.60) 0.023
Depression 
 symptomsa
1.61 (0.85–3.07) 0.145 1.55 (0.85–2.83) 0.148 1.35 (0.79–2.29) 0.271 1.15 (0.69–1.90) 0.593
Childhood  traumaa 1.08 (0.53–2.15) 0.825 1.17 (0.60–2.21) 0.630 1.58 (0.94–2.66) 0.083 1.61 (0.98–2.62) 0.059
Experience 
 violencea,b
2.53 (1.28–5.34) 0.010 2.63 (1.38–5.38) 0.005 1.73 (0.85–3.92) 0.156 1.50 (0.75–3.33) 0.282
Incarcerationa 1.07 (0.58–1.95) 0.823 1.44 (0.81–2.53) 0.212 2.60 (1.37–4.87) 0.003 2.82 (1.54–5.00) 0.001
Regular 
 employmenta,b
1.05 (0.58–1.92) 0.868 1.02 (0.59–1.80) 0.938 0.85 (0.50–1.49) 0.564 0.96 (0.58–1.63) 0.873
Drug  dealinga,b 2.62 (1.28–5.84) 0.012 2.41 (1.22–5.23) 0.017 4.61 (2.08–12.27) 0.001 3.88 (1.78–10.19) 0.002
Sex  worka 0.80 (0.42–1.57) 0.515 0.96 (0.53–1.79) 0.890 0.72 (0.42–1.21) 0.219 0.61 (0.37–1.00) 0.055
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were significantly more likely to engage in daily heroin 
use, binge drug use, and experience violence than those 
who never engaged in NMPOU. Adults who engaged in 
NMPOU were significantly more likely to report over-
dose, accessing methadone treatment, a higher score on 
the Childhood Trauma Questionnaire, and drug deal-
ing regardless of transition trajectory. With the excep-
tion of our finding that males in the youth cohort were 
more likely to transition from NMPOU to illegal drugs 
(vs. transition from illegal drugs to NMPOU), overall 
our results indicate that the transition patterns between 
NMPOU and illegal drugs were not meaningfully 
different with respect to socio-demographic, early life 
risk factors, substance use, income generation, or other 
socio-structural risk factors.
Limitations
This study did not include a sample based on random 
recruitment methods, although extensive street-based out-
reach efforts were undertaken to achieve a diverse sample. 
In addition, the survey responses in this study were subject 
to recall and socially desirable response biases; previous 
research, however, has found that self-reports of drug use 
and related behaviours are valid [17, 18].
Table 3 Multivariate analyses investigating nonmedical prescription opioid use (NMPOU) before or after illegal drug use 
(n = 1345)
a Comparison is yes vs. no
b Refers to activities, behaviours, and experiences in the last 6 months
c Includes injection and non-injection drug use
d Includes crack cocaine, cocaine, or crystal methamphetamine use
e Comparison is <median vs. ≥ median
Characteristic ARYS (n = 512) VIDUS (n = 833)
NMPOU first (vs. never 
NMPOU)
Illicit drugs first (vs. never 
NMPOU)
NMPOU first (vs. never 
NMPOU)




p-value Adjusted odds 
ratio (95% CI)
p-value Adjusted odds 
ratio (95% CI)
p-value Adjusted odds 
ratio (95% CI)
p-value
Age per year older 0.98 (0.95–1.01) 0.128
Male  gendera




Daily heroin  usea,b,c 3.76 (1.33–13.52) 0.022 3.68 (1.37–12.79) 0.019
Daily stimulant 
 usea,b,c,d
Binge drug  usea,b,c 2.05 (1.08–3.95) 0.030 2.07 (1.12–3.90) 0.022




1.81 (1.03–3.19) 0.038 2.43 (1.42–4.19) 0.001
Methadone 
 treatmenta





Childhood  traumaa 1.96 (1.10–3.53) 0.023 1.85 (1.05–3.24) 0.033
Experience 
 violencea,b
2.42 (1.18–5.28) 0.020 2.74 (1.36–5.93) 0.007
Incarcerationa 1.92 (0.93–3.90) 0.072 2.26 (1.11–4.50) 0.021
Regular 
 employmenta,b
Drug  dealinga,b 1.85 (0.87–4.32) 0.127 4.06 (1.72–11.31) 0.003 2.68 (1.17–7.29) 0.032
Sex  worka
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